(Q33392689)

26 July 2017

title

A phase-2 trial of low-dose pomalidomide in myelofibrosis (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

7

A Tefferi

1 reference

26 July 2017

5

M R Litzow

1 reference

26 July 2017

K H Begna

1

1 reference

26 July 2017

R A Mesa

2

1 reference

26 July 2017

A Pardanani

3

1 reference

26 July 2017

W J Hogan

4

1 reference

26 July 2017

R F McClure

6

1 reference

26 July 2017

publication date

5 November 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

25

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

301-304

1 reference

The evolution of thalidomide and its IMiD derivatives as anticancer agents

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

inferred from DOI database lookup

7 January 2021

based on heuristic

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

inferred from DOI database lookup

7 January 2021

based on heuristic

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.254

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.254

1 reference

Dimensions Publication ID

26 July 2017

1037260408

0 references

1 reference